LONG-TERM COST-EFFECTIVENESS MODELING COMPARING MATURITY OF DATA CUTS: A COMPARISON BETWEEN COST-EFFECTIVENESS OF NIVOLUMAB VS EVEROLIMUS IN SECOND LINE RENAL CELL CARCINOMA USING 2-OR 3-YEAR FOLLOW UP CHECKMATE-025 DATA-MedSci.cn

LONG-TERM COST-EFFECTIVENESS MODELING COMPARING MATURITY OF DATA CUTS: A COMPARISON BETWEEN COST-EFFECTIVENESS OF NIVOLUMAB VS EVEROLIMUS IN SECOND LINE RENAL CELL CARCINOMA USING 2-OR 3-YEAR FOLLOW UP CHECKMATE-025 DATA

Sandhu, H; Berardi, A

VALUE IN HEALTH, 2020; 23 (): S44

科室
- - 订阅+
  - 更多科室
工具
服务